PMID- 30416662
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1943-8141 (Print)
IS  - 1943-8141 (Electronic)
IS  - 1943-8141 (Linking)
VI  - 10
IP  - 10
DP  - 2018
TI  - The FENDRR/miR-214-3P/TET2 axis affects cell malignant activity via RASSF1A 
      methylation in gastric cancer.
PG  - 3211-3223
AB  - To explore the effect of fetal-lethal non-coding developmental regulatory RNA 
      (FENDRR) in the initiation and progression of gastric cancer (GC). We detected 
      the levels of FENDRR, microRNA-214-3p (miR-214-3p), and ten-eleven-translocation 
      (TET2) in GC tissues and GC cell lines. In addition, we evaluated the location of 
      FENDRR in GC cell lines by fluorescence in situ hybridization (FISH). Cell 
      proliferation and apoptosis were measured by CCK-8 and Hoechst staining assays. 
      Methylation-specific PCR assay (MSP) was used to evaluate the methylation status 
      of ras-association domain family 1A (RASSF1A). We also observed the direct 
      binding of miR-214-3p on FENDRR by dual-luciferase activity assay in GC cells. 
      FENDRR and TET2 expressions were significantly down-regulated and miR-214-3p was 
      up-regulated in gastric cancer tissues compared to adjacent unaffected tissues. 
      In addition, RASSF1A was hypermethylated in gastric cancer tissues compared to 
      adjacent tissues. The expressions of all the three indicators were influenced by 
      differentiation of tumor, TNM stage of tumors, and lymph node metastasis in 
      patients with GC. A gastric cancer cell line with low FENDRR expression compared 
      to a high FENDRR expressing cell line showed again increased miR-214-3p 
      expression, decreased TET2 and RASSF1A expressions, and RASSF1A hypermethylation, 
      resulting in decreased apoptosis and increased proliferation. Furthermore, we 
      observed a negative correlation between FENDRR and miR-214-3p in GC. The 
      FENDRR/miR-214-3P/TET2 axis plays a critical role in GC progress via methylation 
      of RASSF1A.
FAU - He, Zhaocai
AU  - He Z
AD  - Department of General Surgery, Xiangya Hospital, Central South University 
      Changsha, China.
AD  - Department of General Surgery, Heping Hospital Affiliated to Changzhi Medical 
      College Changzhi, China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of General Surgery, Xiangya Hospital, Central South University 
      Changsha, China.
FAU - Huang, Changhao
AU  - Huang C
AD  - Department of General Surgery, Xiangya Hospital, Central South University 
      Changsha, China.
FAU - Gao, Yu
AU  - Gao Y
AD  - Department of General Surgery, Xiangya Hospital, Central South University 
      Changsha, China.
FAU - Yang, Chen
AU  - Yang C
AD  - Department of General Surgery, Xiangya Hospital, Central South University 
      Changsha, China.
FAU - Zeng, Pengwei
AU  - Zeng P
AD  - Department of General Surgery, Xiangya Hospital, Central South University 
      Changsha, China.
FAU - Chen, Zihua
AU  - Chen Z
AD  - Department of General Surgery, Xiangya Hospital, Central South University 
      Changsha, China.
LA  - eng
PT  - Journal Article
DEP - 20181015
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC6220211
OTO - NOTNLM
OT  - FENDRR
OT  - RASSF1A
OT  - TET2
OT  - gastric cancer
OT  - methylation
OT  - miR-214-3p
OT  - proliferation
COIS- None.
EDAT- 2018/11/13 06:00
MHDA- 2018/11/13 06:01
PMCR- 2018/10/15
CRDT- 2018/11/13 06:00
PHST- 2018/05/29 00:00 [received]
PHST- 2018/09/22 00:00 [accepted]
PHST- 2018/11/13 06:00 [entrez]
PHST- 2018/11/13 06:00 [pubmed]
PHST- 2018/11/13 06:01 [medline]
PHST- 2018/10/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Transl Res. 2018 Oct 15;10(10):3211-3223. eCollection 2018.